Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Stocks Poised to Disrupt the Healthcare Market by 2030
Axsome Therapeutics Recognizes Mental Health Month
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
3 Overlooked Stocks Set to Soar in 2026
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Why Axsome Therapeutics Stock Jumped Over 20% in April
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
US FDA approves Axsome's drug for Alzheimer's-related agitation
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Biotech Stock Knocks At $2 Billion Opportunity, Nears Buy Point
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Moderate Buy” by Brokerages
Is This Healthcare Stock a Millionaire Maker?
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
Critical Contrast: PTC Therapeutics (NASDAQ:PTCT) & Axsome Therapeutics (NASDAQ:AXSM)
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
2 Under-the-Radar Stocks to Buy and Hold
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision
Axsome Therapeutics to Participate in Upcoming Investor Conferences
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued